the use of the cell-cycle conditional mutant strain ( cdc14-1 ) permitted us to apply the second dose at a specific cell-cycle stage ( post-g2 phase ) after a 'priming ' uva treatment on stationary ( g1 ) phase cells .
C0079396
g2 phase
C0007634
cells